VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vaxart, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.48+0.02 (+5.04%)
Close on Oct 19, 2026
- Market cap
- $115.15M
- P/E (TTM)
- 3.2
- Dividend yield
- –
Vaxart, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Government Contract [Member] | $226.12M | $241.59M | $224.52M | $143.45M | $75.93M | $42.56M | $24.86M | $12.85M | $7.96M | $1.60M | $0 | – | 93.0% | +197.8% |
| Non Cash Royalty Revenue [Member] | $403.00K | $392.00K | $1.93M | $4.76M | $4.80M | $4.84M | $3.84M | $3.83M | $4.23M | $4.23M | $3.92M | $776.00K | 0.2% | -91.6% |
| Grant [Member] | – | – | – | – | – | – | $0 | $79.00K | $1.73M | $3.06M | $3.46M | $3.38M | – | – |
By region
From the segment and revenue-disaggregation notes of Vaxart's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.